<b>Supplementary Fig. 1</b> by Richard Babicz (18865600)

“…Erlotinib treatment significantly decreased phospho-ERK levels at both concentrations (figure 1, left). …”

<b>Supplementary Figure 1</b> by Richard Babicz (18865600)

“…Erlotinib treatment significantly decreased phospho-ERK levels at both concentrations (figure 1, left). …”

Image1_Comprehensive analysis of Hibisci mutabilis Folium extract’s mechanisms in alleviating UV-induced skin photoaging through enhanced network pharmacology and experimental vali... by Wenyuan Chen (1770583)

“…In vitro experiments showed that EHMF significantly reduced UV-induced inflammatory factors in HaCaT cells and improved cell survival rates. …”

Image2_Comprehensive analysis of Hibisci mutabilis Folium extract’s mechanisms in alleviating UV-induced skin photoaging through enhanced network pharmacology and experimental vali... by Wenyuan Chen (1770583)

“…In vitro experiments showed that EHMF significantly reduced UV-induced inflammatory factors in HaCaT cells and improved cell survival rates. …”

DataSheet1_Comprehensive analysis of Hibisci mutabilis Folium extract’s mechanisms in alleviating UV-induced skin photoaging through enhanced network pharmacology and experimental... by Wenyuan Chen (1770583)

“…In vitro experiments showed that EHMF significantly reduced UV-induced inflammatory factors in HaCaT cells and improved cell survival rates. …”

Table 2_Tackling global inequalities in maternal hypertensive disorders: trends and the impact of public health emergencies, 1990–2021.csv by Siying Wei (5990276)

“…Disease burden generally decreased with higher SDI levels. Decomposition analysis suggested that demographic factors increased the burden, while epidemiology mitigated it. …”

Image 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Table 1_Tackling global inequalities in maternal hypertensive disorders: trends and the impact of public health emergencies, 1990–2021.csv by Siying Wei (5990276)

“…Disease burden generally decreased with higher SDI levels. Decomposition analysis suggested that demographic factors increased the burden, while epidemiology mitigated it. …”

Image 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Image 1_Tackling global inequalities in maternal hypertensive disorders: trends and the impact of public health emergencies, 1990–2021.tiff by Siying Wei (5990276)

“…Disease burden generally decreased with higher SDI levels. Decomposition analysis suggested that demographic factors increased the burden, while epidemiology mitigated it. …”

Table 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Image 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Image 8_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Image 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Table 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Table 3_Tackling global inequalities in maternal hypertensive disorders: trends and the impact of public health emergencies, 1990–2021.csv by Siying Wei (5990276)

“…Disease burden generally decreased with higher SDI levels. Decomposition analysis suggested that demographic factors increased the burden, while epidemiology mitigated it. …”

Table 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Table 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Table 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”

Image 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Subgroup analyses were performed based on factors such as disease stage, pathological type, etc.…”